More recently, higher plasma MGO levels have been associated with incident CVD in type 1 diabetes (T1D) and with cardiovascular mortality in T2D [178,179], while Glo1 activity is reduced in the atherosclerotic lesion of non-diabetic patients with increased Glycated hemoglobin (HbA1c) [180]. Here, GLO1 is linked to type 2 diabetes mellitus.